Hydroxychloroquine: Anti-malaria drug called 'miracle' by Trump does not prevent Covid-19, study says

The randomised study found taking the drug was no more effective than taking a placebo

What do you have to lose? Take it': Trump pushes unproven drug

The anti-malaria drug hydroxychlorquine, which was previously boasted as a “miracle drug” by Donald Trump, did not prevent Covid-19, according to a new study published in the New England Journal of Medicine.

Researchers from the University of Minnesota and Canada studied 821 people who were exposed to patients infected with the coronavirus.

This clinical trial was the first randomised study to look if hydroxychloroquine had preventive measures against the virus, according to the researchers. Instead, the study found the drug was no more effective than a placebo, a vitamin in this study, in preventing the virus.

“The take-home message for the general public is that if you’re exposed to someone with Covid-19, hydroxychloroquine is not an effective post-exposure, preventive therapy,” the lead author of the study, Dr David R Boulware, from the University of Minnesota, said.

The first trial was launched on 17 March to determine if hydroxychloroquine

“We’re looking at that group and the question of can we give hydroxychloroquine within the first four days post-exposure so we can prevent disease or decrease the severity of this disease,” Dr Boulware previously told The Independent at the start of the trial.

His team also launched a second trial on 23 March for Covid-19 positive patients or those who showed symptoms for the novel virus. Those results have yet to be released.

The latest study comes weeks after a large observational study was published in The Lancet medical journal that studied 96,000 hospitalised coronavirus patients at hundreds of hospitals across six continents.

It found patients who used hydroxycholorquine, or its variant chloroquine, had a significantly higher risk of death than those who did not take the drug. Following the news, the World Health Organisation (WHO) suspended its drug trials, which are now expected to resume shortly.

In recent days, though, scientists have called into question the validity of the observational study using data provided by US company Surgisphere.

The Lancet revealed it had published an “expression of concern” on Wednesday about the study and researchers were conducting an independent review of the data.

The preventive trial just released about hydroxchlorquine’s benefits found 40 per cent of participants developed low-risk side effects, such as nausea and diarrhoea.

None of the participants developed serious side effects such as cardiac abnormalities, which was a concern among health professionals.

In total, about 12 per cent of those who took the drug contracted Covid-19 and 14 per cent of those who took the placebo contracted the virus.

The president repeatedly pushed the drug, over the concerns of medical experts, at one point urging people: "Take it! What have you got to lose?"

Last month he said he had been taking it himself as a preventative measure against Covid-19. On Wednesday his annual medical report was released saying he had shown no side effects from the drug.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in